Arcadia Investment Management Corp MI Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Arcadia Investment Management Corp MI bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, Holdings Channel.com reports. The firm bought 1,155 shares of the company’s stock, valued at approximately $72,000.

Several other large investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in TransMedics Group by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares during the period. Vaughan Nelson Investment Management L.P. increased its stake in TransMedics Group by 9.9% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after buying an additional 32,605 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after buying an additional 6,634 shares in the last quarter. Baillie Gifford & Co. lifted its stake in shares of TransMedics Group by 14.9% in the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after acquiring an additional 34,947 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $71.95 on Friday. The company’s fifty day moving average is $66.47 and its two-hundred day moving average is $105.05. The company has a market cap of $2.41 billion, a P/E ratio of 76.54 and a beta of 2.12. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Canaccord Genuity Group dropped their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Robert W. Baird dropped their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.